Annexon Inc Stock
Annexon Inc Stock price
Key metrics
| Market capitalization | $646.60m |
| Enterprise Value | $336.09m |
| P/E (TTM) P/E ratio | negative |
| P/B ratio (TTM) P/B ratio | 1.95 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-131.60m |
| Cash position | $368.70m |
| EPS (TTM) EPS | $-1.04 |
| P/E forward | negative |
Is Annexon Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
Annexon Inc Stock Analysis
Analyst Opinions
8 Analysts have issued a Annexon Inc forecast:
Analyst Opinions
8 Analysts have issued a Annexon Inc forecast:
Financial data from Annexon Inc
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -3.41 -3.41 |
1%
1%
|
|
| EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -132 -132 |
13%
13%
|
| Net Profit | -118 -118 |
17%
17%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Annexon Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Annexon Inc Stock News
Company Profile
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in South San Francisco, CA.
| Head office | United States |
| CEO | Douglas Love |
| Employees | 71 |
| Founded | 2011 |
| Website | www.annexonbio.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
